When Will Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Become Profitable?

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Suzhou Zelgen

Simply Wall StJul 12 03:53 ET

China's State Drug Administration has accepted the listing application for Zejing Pharmaceutical's (688266.SH) recombinant human thyroid-stimulating hormone.

On June 18th, the official website of the Drug Evaluation Center of the Chinese National Medical Products Administration announced that the application for marketing authorization of the injectable recombinant human thyroid stimulating hormone submitted by Zejing Pharmaceuticals (688266.SH) has been accepted.

Zhitong FinanceJun 18 03:47 ET

Is Suzhou Zelgen BiopharmaceuticalsLtd (SHSE:688266) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor

Simply Wall StJun 13 22:14 ET

Zejiang Pharmaceutical (688266.SH): The Phase III clinical trial of JAK inhibitor GDC-0853 hydrochloride tablets for the treatment of severe alopecia areata has reached the primary endpoint of therapeutic effect.

On June 12th, Gelunhui reported that Zejing Pharmaceuticals (688266.SH) recently announced that the III phase clinical trial of the Type 1 new drug hydrochloride gicasitini tablets (formerly known as hydrochloride jacktitini tablets) independently developed by the company for the treatment of severe alopecia areata, the efficacy and safety of hydrochloride jtiti ni tablets in the treatment of patients with severe alopecia areata were significantly improved (p<0.0001) according to the multicenter, randomized, double-blind, placebo-controlled phase III clinical trial with the plan number of ZGJAK018 reaching the main efficacy endpoint. The company will accelerate the development of hydrochloride gicasitini tablets for the indication of severe alopecia areata.

Gelonghui FinanceJun 12 04:32 ET

Zejing Pharmaceutical (688266.SH): Gicaxitinib hydrochloride tablets obtained drug clinical trial approval notice

Gelonghui, May 29丨Zejing Pharmaceutical (688266.SH) announced that the company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The phase II/III clinical trial of gikaxitinib hydrochloride tablets (formerly known as jacketinib hydrochloride tablets) to treat adolescents and adults aged 12 and above and patients with non-segmental vitiligo was approved.

Gelonghui FinanceMay 29 04:11 ET

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Investors Are Less Pessimistic Than Expected

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) price-to-sales (or "P/S") ratio of 37x may look like a poor investment opportunity when you consider close to half the companies in the Biotec

Simply Wall StMay 14 03:17 ET